Sharlene Haeder

LGD-4033, a novel non steroidal, oral selective androgen receptor modulator (SARMs), binds to the androgen receptor with high affinity and…

LGD-4033, a novel non steroidal, oral selective androgen receptor modulator (SARMs), binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. This is highly effective drug ,
Today this drug has undergone several recent studies & trials to find the best & safest way to use it. These studies giving us good results for losing weight & increasing in strength as well as healing .Keeps always mind fresh & consciousness alert. Work steadily in our body & we feel it naturally.
Muscle Wasting : Now muscle wasting symptoms brings cancer like disease .It reduces muscle waste & this is the first step of cancer .This causes ability to decrease power to take chemotherapy . Brings lot of infections in the chemotherapy or sometimes patient can’t get up from sitting place.
. SARMs increase muscle mass and improve physical function in healthy and diseased individuals, and potentially may provide a new therapy for muscle wasting and cancer cachexia. SARMs modulate the same anabolic pathways targeted with classical steroidal androgens, but within the dose range in This can effects on muscle mass & functions are seen androgenic .That is side effects on hair , prostrate,skin & hair have not been observed. Doing very good job for cancer patients As cancer patients have too much fear about it that is hair loss , effects on skin or muscle effects .So many patients left their hopes during chemotherapy. I think that no any patient is dying due to cancer but misunderstanding about chemotherapy. So before giving therapy patient must have to give counselling in every hospital . Provide these drugs to every patient. .
, SARMs are orally active, nonaromatizable, non-virilizing, and tissue-selective anabolic agents (R).

Share